Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 4/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GALR3 | O60755 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1961068 | 0.90 | CYP11B1 (0.50) | NR1H3NR1H2CYP11B1CYP11B2HPGDS | |
| SCHEMBL1411948 | 0.90 | HPGDS (0.54) | NR1H3NR1H2CYP11B1CYP11B2HPGDS | |
| SCHEMBL1959850 | 0.88 | AHR (0.43) | NR1H3NR1H2CYP11B1CYP11B2HPGDS | |
| SCHEMBL1961421 | 0.87 | CYP11B1 (0.48) | NR1H3NR1H2CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL1961665 | 0.87 | MGAM (0.43) | NR1H3NR1H2CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL1958116 | 0.87 | SMN1; SMN2 (0.50) | NR1H3NR1H2CYP11B1CYP11B2HPGDS | |
| SCHEMBL1958857 | 0.86 | AHR (0.42) | NR1H3NR1H2CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL1961126 | 0.86 | HPGDS (0.45) | NR1H3CYP11B1CYP11B2HPGDSCYP19A1 | |
| SCHEMBL1959643 | 0.86 | SMN1; SMN2 (0.52) | NR1H3CYP11B1CYP11B2HPGDSCYP19A1 | |
| SCHEMBL1959223 | 0.86 | CYP11B1 (0.42) | NR1H3NR1H2CYP11B1CYP11B2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2019-05-16 | — | — | US | claimed |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2017-02-09 | — | — | US | claimed |
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2015-01-08 | — | — | US | claimed |
| US-8779141-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2011-09-08 | — | — | US | claimed |
| EP-1521754-B1 | VIRAL INHIBITORS | LEUVEN K U RES & DEV (BE) | 2011-08-31 | — | — | EP | claimed |
| US-20100004281-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. | 2010-01-07 | — | — | US | claimed |
| US-20050239821-A1 | Viral inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2005-10-27 | — | — | US | claimed |
| EP-1521754-A2 | VIRAL INHIBITORS | K.U.Leuven Research & Development (BE) | 2005-04-13 | — | — | EP | claimed |
| WO-2004005286-A2 | VIRAL INHIBITORS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-01-15 | — | — | WO | claimed |
| EP-2332938-B1 | Viral inhibitors | LEUVEN K U RES & DEV (BE) | 2014-10-01 | — | — | EP | disclosed |
| US-8779141-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8404707-B2 | Imidazo [1, 2-a] pyrrolo [3, 2-c] pyridine compounds useful as pestivirus inhibitors | UNIVERSITE D'AUVERGNE CLERMONT 1 (FR) | 2013-03-26 | — | — | US | disclosed |
| EP-1521754-B1 | VIRAL INHIBITORS | LEUVEN K U RES & DEV (BE) | 2011-08-31 | — | — | EP | disclosed |
| EP-2125807-B1 | IMIDAZO[1,2-A]PYRROLO[3,2-C]PYRIDINE COMPOUNDS USEFUL AS PESTIVIRUS INHIBITORS | UNIV LEUVEN KATH (BE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2125807-A2 | IMIDAZO[1,2-A]PYRROLO[3,2-C]PYRIDINE COMPOUNDS USEFUL AS PESTIVIRUS INHIBITORS | Katholieke Universiteit Leuven (BE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008070937-A2 | IMIDAZO [1, 2-A] PYRROLO [3, 2-C] PYRIDINE COMPOUNDS USEFUL AS PESTIVIRUS INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2008-06-19 | — | — | WO | disclosed |
| US-20050239821-A1 | Viral inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2005-10-27 | — | — | US | disclosed |
| EP-1521754-A2 | VIRAL INHIBITORS | K.U.Leuven Research & Development (BE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005286-A2 | VIRAL INHIBITORS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | NR1H3 4778/4885NR1H2 4814/4885CYP11B1 4499/4885 |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | NR1H3 4778/4885NR1H2 4814/4885CYP11B1 4499/4885 |
| US-20100004281-A1 | VIRAL INHIBITORS | ZC3HAV1, MAVS, HAVCR2 | NR1H3 2655/4885NR1H2 2716/4885CYP11B1 1458/4885 |
| US-20050239821-A1 | Viral inhibitors | ZC3HAV1, ZC3HAV1L, ACE | NR1H3 2044/4885NR1H2 2225/4885CYP11B1 783/4885 |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, MGMT | NR1H3 4768/4885NR1H2 4794/4885CYP11B1 4422/4885 |
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | NR1H3 4778/4885NR1H2 4814/4885CYP11B1 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.